Table 5.
Treatment-related AEs in the patients treated with HAIC
| Grades 1–2, no. (%) | Grades 3–4, no. (%) | |
|---|---|---|
| Any | 54 (84.4) | 8 (12.5) |
| Arterial cannula related | ||
| Catheter dislocation | 3 (4.7) | 0 |
| Catheter obstruction | 2 (3.1) | 0 |
| Arterial thrombosis | 1 (1.6) | 0 |
| Arterial haematoma | 5 (7.8) | 0 |
| Catheter infection | 1 (1.6) | 0 |
| Blood/bone marrow suppression | ||
| Leukocytopenia | 9 (14.1) | 4 (6.3) |
| Neutropenia | 11 (17.2) | 3 (4.7) |
| Thrombocytopenia | 18 (28.1) | 8 (12.5) |
| Hepatic function | ||
| Hyperbilirubinemia | 12 (18.8) | 5 (7.8) |
| AST increase | 12 (18.8) | 6 (9.4) |
| ALT increase | 24 (37.5) | 7 (10.9) |
| GI events | ||
| Abdominal pain | 8 (12.5) | 1 (1.6) |
| Anorexia | 14 (21.9) | 4 (6.3) |
| Vomiting | 19 (29.7) | 2 (3.1) |
| Diarrhea | 9 (14.1) | 4 (6.3) |
| Constitutional symptoms | ||
| Fatigue | 17 (26.6) | 0 |
| Fever | 6 (9.4) | 0 |
AEs, adverse event; HAIC, hepatic artery infusion chemotherapy; AST, aspartate transaminase; ALT, alanine transaminase